Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Girard

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
The European Journal of Neuroscience|September 1, 2025
Frequency Coding of Multisensory Integration in the Local Field Potentials of the Medial PulvinarAnne-Laure Vittek, Cécile Juan, Corentin Gaillard, et al.
The AAPS Journal|March 19, 2020
Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall SurvivalDiego Vera-Yunca, Pascal Girard, Zinnia P Parra-Guillen, et al.
Clinical Pharmacology and Therapeutics|August 12, 2024
Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal CancerAna-Marija Milenković-Grišić, Siobhán Hayes, Colm Farrell, et al.
The Prostate|May 29, 2009
Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomyBenoit You, Pascal Girard, Philippe Paparel, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2022
Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity modelsKristyn Pantoja, Shankar Lanke, Alain Munafo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamicsLaurent Claret, Pascal Girard, Paulo M Hoff, et al.
Orphanet Journal of Rare Diseases|May 31, 2011
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimenInes Paule, Hind Sassi, Anoosha Habibi, et al.
Clinical Pharmacokinetics|May 1, 2007
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host diseaseCéline Dartois, Gilles Freyer, Mauricette Michallet, et al.
Clinical Pharmacokinetics|March 3, 2007
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004Karl Brendel, Céline Dartois, Emmanuelle Comets, et al.
Arzneimittel-Forschung|June 29, 2002
Bioequivalence evaluation of a fixed combination of chloroquine and proguanil in a capsule formulation versus a standard medicationJean François Chaulet, Patrice Nony, Fabien Bévalot, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
The European Journal of Neuroscience|September 1, 2025
Frequency Coding of Multisensory Integration in the Local Field Potentials of the Medial PulvinarAnne-Laure Vittek, Cécile Juan, Corentin Gaillard, et al.
The AAPS Journal|March 19, 2020
Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall SurvivalDiego Vera-Yunca, Pascal Girard, Zinnia P Parra-Guillen, et al.
Clinical Pharmacology and Therapeutics|August 12, 2024
Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal CancerAna-Marija Milenković-Grišić, Siobhán Hayes, Colm Farrell, et al.
The Prostate|May 29, 2009
Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomyBenoit You, Pascal Girard, Philippe Paparel, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2022
Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity modelsKristyn Pantoja, Shankar Lanke, Alain Munafo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamicsLaurent Claret, Pascal Girard, Paulo M Hoff, et al.
Orphanet Journal of Rare Diseases|May 31, 2011
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimenInes Paule, Hind Sassi, Anoosha Habibi, et al.
Clinical Pharmacokinetics|May 1, 2007
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host diseaseCéline Dartois, Gilles Freyer, Mauricette Michallet, et al.
Clinical Pharmacokinetics|March 3, 2007
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004Karl Brendel, Céline Dartois, Emmanuelle Comets, et al.
Arzneimittel-Forschung|June 29, 2002
Bioequivalence evaluation of a fixed combination of chloroquine and proguanil in a capsule formulation versus a standard medicationJean François Chaulet, Patrice Nony, Fabien Bévalot, et al.
Pageof 8